RefleXion Medical awarded $1.5MM Phase II SBIR grant from the National Cancer Institute
September 15, 2014
Major Support From National Cancer Institute to Accelerate Development of Biologically-Guided Radiotherapy System
BURLINGAME, CA–(Marketwired – September 15, 2014) – RefleXion Medical Inc. announced today that it has been awarded a $1.5MM Small Business Innovation Research (SBIR) Phase II grant from the National Cancer Institute (NCI).
During the 27 month project, entitled “Rotating PET and linear accelerator system for PET-guided radiation therapy,” RefleXion will continue development of its revolutionary biologically-guided radiotherapy system for cancer treatment.
“The SBIR Phase II award from the National Cancer Institute validates the potential of RefleXion’s PET-guided system and is crucial support complementing our existing venture capital financing,” said Dr. Samuel Mazin, the Principal Investigator on the grant and President of RefleXion.
“The RefleXion system will enable simultaneous PET imaging and delivery of therapeutic radiation in a fast rotating gantry,” said Dr. David Townsend, Co-inventor of the combined PET/CT scanner and Director at A*STAR-NUS Clinical Imaging Research Centre, Singapore, “I am very excited to be contributing to RefleXion’s ground-breaking program as a grant Co-investigator.”
“Biologically-guided and personalized radiotherapy would result in improved tumor targeting and reduced toxicity, representing a logical evolution in cancer treatment and could open up significant new clinical applications,” said Dr. Jim Welsh, Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center and a member of RefleXion’s Scientific Advisory Board.